Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1353507

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to ensure long term monitoring of immunity in people who have received different covid-19 vaccines for each dose.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	44365
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The National Institute for Health Research has commissioned the National Immunisation Schedule Evaluation Consortium to undertake the Com-CoV trial. This trial is gathering data on the long-term immune response of using different COVID-19 vaccines for the first and second dose.</p><p>Public Health England has also undertaken follow up on people given mixed schedules as part of routine care to monitor self-reported side effects and antibody response. The antibody results will be published in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:07:39 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4385 label Biography information for Dr Philippa Whitford

1353594

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the risk covid-19 poses to unvaccinated pregnant women; and what steps he is taking to ensure pregnant women receive both doses of the vaccine before their third trimester.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	44411
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>Although the overall risk from COVID-19 in pregnant women is low, in later pregnancy some women may become seriously unwell and need hospital treatment. Pregnant women with COVID-19 have a higher risk of intensive care admission than women of the same age who are not pregnant. Women with COVID-19 disease are also 2-3 times more likely to have their babies early than women without COVID-19. Pregnant women with underlying clinical conditions are at even higher risk of suffering serious complications from COVID-19.</p><p> </p><p>Currently, the Joint Committee on Vaccination and Immunisation (JCVI) recommends an interval of 8 weeks between doses of all the available COVID-19 vaccines; this includes pregnant women. It is important to note that current evidence shows that a longer dose interval produces a better immune response. The JCVI regularly reviews its advice in relation to COVID-19 Vaccination Programme, taking into account new data and evidence on the effectiveness of the programme and epidemiological situation.</p><p> </p><p>We are working hard to drive uptake in pregnant women, to ensure that as many pregnant women take up the offer of vaccination as soon as possible so that they are protected throughout their pregnancy. It is understood that pregnant women may prefer to wait to be vaccinated until after they have given birth. It is important for pregnant women to discuss their offer of vaccination with a healthcare professional in relation to the risks and benefits of the vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 13:44:02 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4510 label Biography information for Helen Hayes

1352871

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many covid-19 vaccines have been disposed of that were (a) out of date (b) unused to date.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	43653
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The information requested is not currently centrally held. Work is ongoing across the vaccination programme to standardise and increase the information available for management purposes.</p><p>We have put in place robust mitigations throughout the vaccination programme to reduce wastage, manage expiry dates, and avoid vaccine destruction.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 11:00:27 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4658 label Biography information for Alex Sobel

1352957

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence his Department holds on the potential benefits of immunisation against covid-19 for people who have previously tested positive for that virus.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	43644
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>It is not known how long antibodies made in response to natural COVID-19 infection persist, and whether immunisation could offer more protection. However, it is expected the COVID-19 vaccine would boost any pre-existing antibodies from previous infection. There is no evidence of any safety concerns from vaccinating individuals with a history of COVID-19 infection or with detectable antibodies to COVID-19. Therefore, people who have had COVID-19 disease – whether confirmed or suspected – should still receive the COVID-19 vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:12:09 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1353027

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the data and evidential basis which supports the decision of the Joint Committee on Vaccination and Immunisation to authorise administration of a covid-19 vaccine to people aged 16 and 17.
tabling member constituency	Gateshead
tabling member printed	Ian Mearns
uin	43491
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s advice on vaccination of those aged 16 to 17 years old was published on 4 August 2021. The statement sets out the basis for the advice and includes references to supporting evidence and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years" target="_blank">https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 09/09/2021 16:39:03 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4000 label Biography information for Ian Mearns

1353036

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS Covid Pass
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with relevant stakeholders to help ensure that people who received doses of the AstraZeneca covid-19 vaccine produced in India are able to demonstrate their vaccination status when travelling overseas.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	43526
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>The Government continues to liaise with international partners and other organisations, such as the International Civil Aviation Organization and the World Health Organization, to support the work on certification to ensure that global travel is unhindered and supported by a common approach.</p><p>All doses of AstraZeneca COVID-19 vaccines manufactured in India and administered in the United Kingdom are the same product, under the same authorisation as all other AstraZeneca vaccine doses deployed in the UK, now known commercially Vaxzevria. They appear on the NHS COVID Pass as such, which has been available for international travel since May. Decisions on which vaccines countries will accept at their borders are for respective Governments and we continue to actively engage with these countries to ensure all AstraZeneca doses administered in the UK, including those manufactured in India, are recognised.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 09/09/2021 16:41:39 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4267 label Biography information for Sarah Champion

1352198

registered interest
date	03/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether people who normally receive a flu vaccination, including people with asthma and lung conditions, will receive a covid-19 booster vaccination in autumn 2021.
tabling member constituency	Leeds Central
tabling member printed	Hilary Benn
uin	41664
answer	answer is ministerial correction date of answer 08/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) interim advice is that COVID-19 booster vaccinations should first be offered to the most vulnerable. The JCVI advises a two stage approach, with individuals in stage one offered a booster vaccine and flu vaccine, as soon as possible from September. Individuals in stage two would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at risk group, including some patients with chronic respiratory disease and asthma are currently included in stage two.</p><p>Final decisions on the timing and scope and cohort eligibility, booster programme will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 42174 question first answered 08/09/2021 15:14:12 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	413 label Biography information for Hilary Benn

1352226

registered interest
date	03/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether coeliac disease is an eligible condition for children to receive the covid-19 vaccination; and what steps his Department is taking to ensure that children's eligibility for that vaccination is decided consistently across GP practices.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	41854
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation advises that asplenia or dysfunction of the spleen constitutes a risk group for the purpose of COVID-19 vaccination of children. Hyposplenism or reduced spleen function in coeliac disease is uncommon in children and the prevalence correlates with the duration of exposure to gluten. Therefore, children diagnosed with coeliac disease early in life whose condition is well managed are unlikely to require vaccination.</p><p>Clinical judgment should be applied in identifying these children on a case by case basis.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:17:38 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4079 label Biography information for Julian Sturdy

1352544

registered interest
date	03/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the findings of (a) the ONS that chronic lower respiratory disease is the third most common underlying condition with death as a result of covid-19 in quarter 2 of 2021 and (b) of the British Lung Foundation, in its 2012 survey, that 81 per cent of chronic lower respiratory disease is asthma, if he will make it his policy that people with asthma who receive a free annual flu vaccination will be included in any covid-19 booster vaccination programme.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	42174
answer	answer is ministerial correction date of answer 08/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) interim advice is that COVID-19 booster vaccinations should first be offered to the most vulnerable. The JCVI advises a two stage approach, with individuals in stage one offered a booster vaccine and flu vaccine, as soon as possible from September. Individuals in stage two would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at risk group, including some patients with chronic respiratory disease and asthma are currently included in stage two.</p><p>Final decisions on the timing and scope and cohort eligibility, booster programme will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 41664 question first answered 08/09/2021 15:14:11 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4784 label Biography information for Duncan Baker

1352693

registered interest
date	03/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to provide similar guidance to the temporary clinical authorisation granted by the Medicine and Healthcare Products Regulatory Agency (MHRA) to the Pfizer/BioNtech vaccine on 2 December 2020, to the MHRA in regards to the fast-tracking of nasal covid-19 vaccines; and if he will make a statement.
tabling member constituency	Broxbourne
tabling member printed	Sir Charles Walker
uin	41742
answer	answer is ministerial correction date of answer 08/09/2021 answer text <p>COVID-19 vaccines which can be administered nasally are currently in early clinical trials. Any route to approval of such treatments will be subject to the developer seeking regulatory approval from the United Kingdom’s independent medicines regulator, the Medicines and Healthcare products Regulatory Agency.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 08/09/2021 13:59:54 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1493 label Biography information for Sir Charles Walker